SPY330.65-3.85 -1.15%
DIA276.52-2.38 -0.85%
IXIC10,793.28-117.00 -1.07%

Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $190

Chardan Capital maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $150 to $190.

Benzinga · 12/19/2019 12:48

Chardan Capital maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $150 to $190.